secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2026-05-15T20:03:00+00:00
Accession:  0001628280-26-035542
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics CFO Adams assumes principal accounting officer; Mossler departs
-------------------------------------------------------------------------------

- Mark Mossler to cease as Chief Accounting Officer effective May 15, 2026; departure not due to any disagreement.
- CFO Kendra R. Adams designated as principal accounting officer, effective May 15, 2026.
- Adams receives no additional compensation for assuming the additional role.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828026035542/0001628280-26-035542-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828026035542/cccc-20260515.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-035542

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer